COVID-19 Information
BioAegis is currently evaluating data from our Phase 2 clinical study of recombinant human plasma gelsolin (rhu-pGSN) added to standard of care for treatment of patients with severe COVID-19 pneumonia. Primary outcome measures will evaluate efficacy and safety. Specific details of the protocol can be reviewed at: https://clinicaltrials.gov/ct2/show/NCT04358406 (March 2021)
This human protein enhances the body’s ability to manage excess inflammation without suppressing immune function, unlike currently approved anti-inflammatory treatments.
Stage
Phase 2
Company Type
Late Onset Intervention